| Fuelling advances in paediatric lung health | Lancet Respiratory Medicine | 15 hours | save |  |  |  |  |
| Positivity and pulmonary rehabilitation: antidotes to chronic lung conditions | Lancet Respiratory Medicine | 15 hours | save | | | | |
| Preparing for the future implementation of respiratory syncytial virus vaccines | Lancet Respiratory Medicine | 1 day | save | | | | |
| Where next for inhaled corticosteroids in childhood asthma? | Lancet Respiratory Medicine | 2 days | save | | | | |
| Reducing stigma around smoking would encourage more early lung cancer screening | Lancet Respiratory Medicine | 5 days | save | | | | |
| Headway made towards biosignatures for incipient tuberculosis | Lancet Respiratory Medicine | 5 days | save | | | | |
| Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis | Lancet Respiratory Medicine | 5 days | save | | | | |
| Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | Lancet Respiratory Medicine | 7 days | save | | | | |
| Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer | Lancet Respiratory Medicine | 7 days | save | | | | |
| Young non-smoker diagnosed with lung cancer | Lancet Respiratory Medicine | 8 days | save | | | | |
| A critical approach to personalised medicine in ARDS | Lancet Respiratory Medicine | 9 days | save | | | | |
| Information overload and unsustainable workloads in the era of electronic health records | Lancet Respiratory Medicine | 9 days | save | | | | |
| Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials | Lancet Respiratory Medicine | 9 days | save | | | | |
| Nintedanib for systemic sclerosis-associated interstitial lung disease | Lancet Respiratory Medicine | 12 days | save | | | | |
| Organising international research in critical care medicine: current challenges and potential solutions | Lancet Respiratory Medicine | 36 days | save | | | | |
| The Cigarette: A Political History, Sarah Milov. Harvard University Press (2019), 394, ISBN: 978-0674241213 | Lancet Respiratory Medicine | 37 days | save | | | | |
| Planning for the next pandemic: a call for new guidance | Lancet Respiratory Medicine | 37 days | save | | | | |
| A public health emergency among young people | Lancet Respiratory Medicine | 40 days | save | | | | |
| Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial | Lancet Respiratory Medicine | 41 days | save | | | | |
| Treatment for obstructive sleep apnoea and cardiovascular diseases: are we aiming at the wrong target? | Lancet Respiratory Medicine | 41 days | save | | | | |
| Will biomarkers be the answer for antibiotic stewardship? | Lancet Respiratory Medicine | 50 days | save | | | | |
| Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation | Lancet Respiratory Medicine | 50 days | save | | | | |
| Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial | Lancet Respiratory Medicine | 51 days | save | | | | |
| Active management of mild obstructive sleep apnoea: the evidence grows | Lancet Respiratory Medicine | 51 days | save | | | | |
| Life after tuberculosis: planning for health | Lancet Respiratory Medicine | 58 days | save | | | | |
| Familial lung disease presenting in reverse | Lancet Respiratory Medicine | 58 days | save | | | | |
| Life-threatening bronchiolitis in children: eight decades of critical care | Lancet Respiratory Medicine | 65 days | save | | | | |
| Correction to Lancet Respir Med 2019; published online Nov 6. https://doi.org/10.1016/S2213-2600(19)30418-7 | Lancet Respiratory Medicine | 68 days | save | | | | |
| American Thoracic Society calls for more research into military deployment respiratory exposures | Lancet Respiratory Medicine | 68 days | save | | | | |
| US States confront oil and gas drilling health hazards | Lancet Respiratory Medicine | 69 days | save | | | | |
| Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? | Lancet Respiratory Medicine | 71 days | save | | | | |
| Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial | Lancet Respiratory Medicine | 71 days | save | | | | |
| Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study | Lancet Respiratory Medicine | 72 days | save | | | | |
| Austria bans smoking in bars and restaurants | Lancet Respiratory Medicine | 72 days | save | | | | |
| Microbiological outliers in cystic fibrosis: resolving uncertainty | Lancet Respiratory Medicine | 72 days | save | | | | |
| E-cigarette regulation: getting it wrong costs lives | Lancet Respiratory Medicine | 75 days | save | | | | |
| E-cigarettes: banning flavours is better than an outright ban | Lancet Respiratory Medicine | 75 days | save | | | | |
| E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach | Lancet Respiratory Medicine | 75 days | save | | | | |
| Understanding and improving quality of care in preschool wheeze | Lancet Respiratory Medicine | 76 days | save | | | | |
| WHO global progress report on tuberculosis elimination | Lancet Respiratory Medicine | 77 days | save | | | | |
| The Cave | Lancet Respiratory Medicine | 77 days | save | | | | |
| Non-eosinophilic severe exacerbations of COPD: what about antibiotics? – Authors' reply | Lancet Respiratory Medicine | 77 days | save | | | | |
| Non-eosinophilic severe exacerbations of COPD: what about antibiotics? | Lancet Respiratory Medicine | 83 days | save | | | | |
| RISE-IIP: some pitfalls and observations | Lancet Respiratory Medicine | 91 days | save | | | | |
| Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial | Lancet Respiratory Medicine | 92 days | save | | | | |
| Early-life exposure to electronic cigarettes: cause for concern | Lancet Respiratory Medicine | 92 days | save | | | | |
| Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial | Lancet Respiratory Medicine | 92 days | save | | | | |
| Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial | Lancet Respiratory Medicine | 92 days | save | | | | |
| Pneumonia research: time to fill in the gaps | Lancet Respiratory Medicine | 97 days | save | | | | |
| Pulse oximetry in paediatric primary care in low-income and middle-income countries | Lancet Respiratory Medicine | 97 days | save | | | | |
| | 
report | next » |
| |
